Specific diseases
Update on magnetic resonance imaging and ultrasound in rheumatoid arthritis
J.F. Baker1, P.G. Conaghan2, F. Gandjbakhch3
- Philadelphia Veterans’ Affairs Medical Center, School of Medicine, Division of Rheumatology, University of Pennsylvania Perelman School of Medicine, and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA.
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds UK.
- Université Pierre et Marie Curie, Paris 6, Sorbonne Universités, GRC-08 (EEMOIS); APHP, Rheumatology Department, Pitié Salpêtrière University Hospital, Paris France.
CER11698
2018 Vol.36, N°5 ,Suppl.114
PI 0016, PF 0023
Specific diseases
Free to view
(click on article PDF icon to read the article)
PMID: 30296974 [PubMed]
Received: 03/09/2018
Accepted : 03/09/2018
In Press: 01/10/2018
Published: 01/10/2018
Abstract
Rheumatoid arthritis (RA) disease activity often remains difficult to assess and quantify accurately. As a result, numerous measures using various techniques to estimate clinical activity have been developed for clinical research and care. More objective imaging biomarkers for early detection and accurate, quantitative measurement of the disease burden are therefore of interest both for clinical use and for investigational studies. Two widely studied imaging biomarkers are magnetic resonance imaging (MRI) and ultrasound (US), imaging tests that are increasingly available to clinicians. While substantial and increasing evidence has been reported that these tools are valid and provide advantages in both clinical trials and clinical assessments, more information is needed to inform their appropriate use in routine clinical care. The goals of this review are to outline the current literature regarding each of these objective imaging tools, assess their strengths and limitations, and to clarify knowledge gaps to be filled before these techniques may be more optimally utilised.
